ABSTRACTSince the emergence of CoVID-19 pandemic in China in late 2019, scientists are striving hard to explore non-toxic, viable anti-SARS-CoV-2 compounds or medicines. We determined In Vitro anti-SARS-CoV-2 activity of oral formulations (syrup and capsule) of an Iodine-complex (Renessans). A monolayer of vero cells were exposed to SARS-CoV-2 in the presence and absence of different concentrations (equivalent to 50, 05 and 0.5 μg/ml of I2) of Renessans. Anti-SARS-CoV-2 activity of each of the formulation was assessed in the form of cell survival, SARS-CoV-2-specific cytopathic effect (CPE) and genome quantization. With varying concentrations of syrup and capsule, a varying rate of inhibition of CPE, cells survival and virus replication was observed. Compared to 0.5 μg/ml concentration of Renessans syrup, 5 and 50 μg/ml showed comparable results where there was a 100% cell survival, no CPEs and a negligible viral replication (ΔCT= 0.11 and 0.13, respectively). This study indicates that Renessans, containing iodine, may have potential activity against SARS-CoV-2 which needs to be further investigated in human clinical trials.

Metasurface-based intelligent reflecting surfaces constitute a revolutionary technology which can serve the purpose of alleviating the blockage problem in mmwave communication systems. In this work, we consider the hypersurface paradigm complementing the software defined metasurface with an embedded controller network in order to facilitate the dissemination of reconfiguration directives to unit cell controllers. For the first time, we describe the methodology with which to characterize the workload within this embedded network in the case of the metasurface tracking multiple users and we use a vehicular communications setting to showcase the methodology. Beyond that, we demonstrate use cases of the workload analysis. We show how the workload characterization can guide the design of information dissemination schemes achieving significant reduction in the network traffic. Moreover, we show how the workload, as a measure of the consumed power, can be used in designing energy efficient communication protocols through a multi-objective optimization problem maximizing the achieved utilization while at the same time minimizing the workload incurred.

No abstract

Յ18kg in 7/11). At baseline 6 patients were NYHA Class II and 5 were Class III. Clinical procedural success was achieved in 9/11. One patient experienced a major ischemic stroke (MRSϭ3 at discharge; final 90-day adjudication pending). A second had a mean post-procedure gradient of 22mmHg (above the 20mmHg VARC threshold) although the valve was functioning well (post-procedure AVA 1.6cm2). Partial resheathing was performed in 4/4 patients; none required full retrieval. Mean aortic gradient was 53.9Ϯ20.9mmHg at baseline and 13.7Ϯ3.7mmHg at discharge. Mean AVA was 0.7Ϯ0.2cm 2 at baseline and 1.5Ϯ0.2cm 2 at discharge. Paravalvular AR was mild in 2 patients, trivial in 1, absent in 8. Conduction disturbance requiring a new pacemaker occurred in 4 patients (2 with complete AV block). There were no deaths or MIs through 7 days. Conclusions: Early feasibility results suggest that the Lotus Valve can be positioned precisely and successfully with virtually no AR and low clinical event rates through discharge, supporting further study in a larger, more rigorous trial. Three-month data will be presented for the first time at TCT 2012.Background: Long-term blood-pressure (BP) monitoring is a vital necessity for physicians to prescribe appropriate medical treatment for malign hypertension patients in order to reduce the incidence of secondary consequences such as stroke, kidney failure or heart insufficiency. However, current devices are still not suited for long-term measurement (several weeks to months). Moreover, they usually measure the peripheral blood pressure which significantly differs to the central blood pressure known to be the better indicator for vascular diseases. In order to address this need, we developed and conducted in-vivo tests on a novel, fully-implantable, wireless blood-pressure monitoring system. Methods: The monitoring system was tested for six months in 12 chronic ovine models. The sensor was implanted with X-ray-control in the femoral artery by means of a dedicated sheath (PASIS). Reference measurements were recorded with gold standard pressure sensors after implantation. Position and proper functioning of the sensor were controlled via regular readout measurements and CTs. At the end of each trial, a histological examination was conducted. Results: Chronic in-vivo studies revealed that blood pressure measurement over a period of six months was possible with the novel implantable sensor system. Stable pressure histories were recorded. However, the mechanical resilience of the sensor system requires improvement. The in-vivo tests in the femoral artery of sheep produced high stress on the sensors system. Several implanted systems became inoperative despite efforts to stiffen the sensor-cable. The histological analysis detected no thrombi. Mild inflammatory reactions were found at the vessel insertion site in several cases. Conclusions:The results of the chronic in-vivo tests on the novel fully-implantable blood-pressure monitoring system were encouraging. Improvements need to be made regarding the mec...